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Abstract
Background: Despite successful primary reperfusion therapy, patients may develop large 
myocardial infarction related in part to reperfusion injury. Induction of mild therapeutic hy-
pothermia (TH) applied in patients has demonstrated beneficial effect in reducing reperfusion 
injury. The aim of the study was to evaluate the feasibility and safety of adjunctive mild TH 
to primary percutaneous coronary intervention (PPCI) in patients with acute ST elevation 
myocardial infarction (STEMI) complicated with cardiogenic shock (CS).
Methods: We conducted a prospective single center, open label, historical control study. Pa-
tients presenting with STEMI and CS despite maximal support therapy scheduled for PPCI 
were included. Death was defined as primary endpoint. Secondary outcomes included: TH 
adverse effect — such as fever, refractory hypotension and arrhythmias, infarct size measured 
by area under the curve of biomarkers.
Results: Eight consecutive patients were prospectively enrolled (TH group). Thirteen clinically 
similar patients identified from our database, admitted over 2 years, comprised the historical 
control group (control group). In the hypothermia group, the mortality was 50% compared with 
46% in the control group. There was no difference in the secondary outcomes.
Conclusions: TH as adjunctive therapy in STEMI patients complicated with CS is feasible 
and safe. Based on these preliminary observations there appears to be no significant clinical 
advantage to this form of therapy. (Cardiol J 2015; 22, 3: 285–289)
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Introduction
Cardiogenic shock (CS) affects approximately 
5% to 7% of patients with myocardial infarction (MI) 
and is the leading cause of death among hospital-
ized patients with MI, with mortality approaching 
50% despite urgent reperfusion therapy, optimal 
medical care, and intra-aortic balloon support [1].
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Therapeutic hypothermia (TH) is the stand-
ard of care in the treatment for out-of-hospital 
ventricular tachycardia/fibrillation arrest. The 
potential beneficiary neuroprotective effect is by 
reducing reperfusion injury [2]. Theoretically, the 
cooling properties of TH that protect the brain 
and promote recovery after cardiac arrest may 
have similar effects on other vital organs, such as 
the infracted heart and other injured organs due 
to CS. The cardioprotective effects of TH have 
been reported for over 30 years [3]. The benefit 
of mild TH as a treatment for acute MI (AMI) has 
now been demonstrated in several animal models 
[4] and small to intermediate scale feasibility 
randomized clinical trials [5–7]. A small reduction 
in temperature (2–4°C) may result in a profound 
reduction effect on infarct size [8]. Experimental 
studies have shown that there is a strong correla-
tion between infarct size and body temperature 
and the size of ischemic risk zone, which becomes 
necrotic dependent on temperature. In humans, the 
adjunctive intravascular cooling before mechanical 
reperfusion in uncomplicated AMI appears to be 
safe and may reduce infarct size without significant 
delay in the door to balloon time [9]. Recently, it 
has been proposed that CS is a systemic illness 
that needs systemic treatment, such as TH [10]. 
There are yet no clinical studies investigating 
prospectively the effect of TH in patients with CS 
following AMI.
The aim of this study was to evaluate the safe-
ty and feasibility of non-invasive cooling induction 
as adjuvant therapy in patients with a ST-elevation 
MI (STEMI) complicated with CS scheduled to 
undergo primary percutaneous coronary interven-
tion (PPCI).
Methods
Ethics
The present study was performed in accord-
ance with the Declaration of Helsinki. The study 
protocol was approved by the local Ethics Commit-
tee. Since all included patients had been sedated 
and invasively ventilated, the authors were exempt 
from obtaining prospective written informed con-
sent. Close family members received detailed ex-
planation about the study aims and protocol. After 
the patients’ recuperation and rehabilitation, the 
study protocol was given to all surviving patients.
Study population
It was a single center, prospective, open label, 
historical control study. Patients were enrolled to 
test the feasibility and safety of an infusion of cold 
normal saline at 4oC at a high rate, alongside to 
a designated hypothermia suit, as an adjunct therapy 
in patients with an acute coronary syndrome com-
plicated with pump failure CS eligible for PPCI. 
Men and women between 18 and 75 years of age 
who presented with an anterior or inferior STEMI 
with ST-segment elevation of 0.2 mV in 2 or more 
anatomically contiguous leads or ST depression of 
0.3 mV or more in V3–V4 and a duration of symp-
toms of < 12 h were included. Pump failure CS 
was defined as persistent hypotension, systolic 
pressure < 90 mm Hg despite fluids and catechola-
mine infusion. Patients with cardiac arrest, known 
congestive heart failure, significant valve disease, 
CS related to any mechanical complication (rupture 
free wall, ventricular septal defect, tamponade, 
acute mitral regurgitation, significant right ventri-
cle infarction), end-stage kidney disease or hepatic 
failure, recent stroke, coagulopathy or pregnancy, 
or absence of maximal support therapy, were ex-
cluded from the study.
Protocol
Eligible patients were prospectively assigned 
to TH group. Mild TH (32–34oC) was applied for 
12 h; non-invasive induction was obtained by 
combining an IV infusion of normal saline at 4oC 
at a 5–15 mL/kg/h rate, alongside to a designated 
hypothermia suit. After induction, hypothermia 
was maintained by the suit only. Body core tem-
perature was monitored independently using 
3 separate probes. Re-warming was initiated after 
12 h of hypothermia at a rate of 0.3oC per hour. 
All patients were sedated with midazolam and 
a muscle relaxant in order to prevent shivering. 
Once normal body temperature was regained, 
sedation was halted. After induction of hypother-
mia started, coronary angiogram was performed. 
Loading doses of 300 mg of aspirin and 600 mg of 
clopidogrel were given to all patients before cardiac 
catheterization. Patients underwent PCI according 
to current standard of practice.
The historical control group was selected 
based on similar inclusion criteria.
The primary outcome measure was death at 
30 days. The secondary outcome measure was 
MI size, assessed by cardiac markers (troponin 
T and creatinine kinase [CK]) and TH related 
complications such as infection or refractory 
arrhythmias.
Biochemical markers
Troponin T and CK were sampled on admission 
to the catheterization laboratory, and at 12 h and 
24 h after admission. Peak values were defined as 
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the highest measured value within 24 h. The area 
under the curve (AUC) was calculated in each 
patient.
Statistical analysis
Standard statistical calculations were used. 
Comparison between groups was based on the 
unpaired t-test, statistical significance was defined 
as p < 0.05.
Results
Twenty-one patients were enrolled into the 
study: 8 patients prospectively in the TH group and 
13 in the historical control group (normothermia 
group). There were no significant differences in 
baseline characteristics between the hypothermia 
and the control groups (Table 1). Laboratory and 
angiographic data are shown in Table 2. Success-
Table 1. Patients’ baseline characteristics.
Active group
(hypothermia, n = 8)
Control group
(normothermia, n = 13)
P
Age (median) 69.6 ± 7 65.1 ± 10 NS
Male 6 9 NS
Hypertension 5 11 NS
Diabetes mellitus 3 6 NS
Dyslipidemia 6 7 NS
Current smoker 5 4 NS
Past myocardial infarction 3 6 NS
Chronic renal failure 3 6 NS
ST elevation myocardial infarction 7 11 NS
Non-ST elevation myocardial infarction 1 2 NS
Anterior myocardial infarction 7 9 NS
Non-anterior myocardial infarction 1 4 NS
Subacute stent thrombosis 1 1 NS
Late stent thrombosis 0 1 NS
Table 2. Angiographic, procedural and laboratory data.
Active group
(hypothermia, n = 8)
Control group
(normothermia, n = 13)
P
Door-to-balloon time [min] 79 ± 21 86 ± 26 NS
Infarct related artery: NS
Left main 2 4 NS
Left anterior descending artery 5 6 NS
Right coronary artery 1 3 NS
Non culprit PCI 4 5 NS
Initial TIMI flow: NS
0/1 6 11 NS
2/3 2 2 NS
Successful reperfusion 8 13 NS
Final TIMI flow 3 6 10 NS
Non reflow phenomenon 4 6 NS
Median peak creatinine kinase (12 h) 4,200 ± 424 5,906 ± 525 NS
Median creatinine kinase (72 h) 1,637 ± 272 2,894 ± 263 NS
Area under the curve (72 h) 7,343 ± 5,742 14,361 ± 10,197 NS
PCI — percutaneous coronary intervention; TIMI — Thrombolysis in Myocardial Infarction
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ful revascularization was achieved in all patients 
and a stent was inserted in all with Thrombolysis 
in Myocardial Infarction (TIMI) 3 flow at the end 
of the procedure.
Hypothermia treatment
Baseline temperature was similar in the two 
groups (36.5 ± 0.6°C vs. 36.6 ± 0.8°C, TH vs. 
control, p < 0.69). Door-to-balloon time was 
79 ± 21 min in the TH group and 86 ± 26 min 
in the control group, indicating that induction of 
hypothermia did not cause any significant delay in 
time to reperfusion (p < 0.22) In the TH group, at 
the time of reperfusion, core body temperature was 
35 ± 0.7°C. The target temperature was achieved 
118 ± 27 min after induction. The maintenance 
phase extended by over 12 h in all 8 patients.
Clinical events/safety
There were no significant differences between 
the groups with regard to clinical events (Fig. 1). 
In the TH group, the mortality at 7 days was 50% 
compared with 46% in the control group. The sur-
viving patients in the TH group returned to good 
functional class at 6 months and 3 of the 4 alive 
patients had some systolic function recuperation 
at 3-month echocardiography assessment. There 
were no differences in the incidence of fever, infec-
tion, significant arrhythmia or blood transfusion 
between the two groups (Fig. 2).
Biochemical markers
Peak CK (Fig. 3) and troponin T levels did not 
differ between the groups, although a mild trend 
toward reduction was observed in the TH group 
Figure 4. Calculated area under the curve.
Figure 1. Patients survival at 7 and 30 days; TH — thera-
peutic hypothermia
Figure 2. Hospital complications; TH — therapeutic hy-
pothermia; ARF — acute renal failure.
Figure 3. Peak creatinine kinase (CK) levels release.
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(4,200 ± 424 vs. 5,096 ± 525 g/L, p = 0.17 and 
8.8 ± 4.3 vs. 8.02 ± 5.4 µg/L, p = 0.11, respectively 
between the TH vs. control). The AUC for total 
CK calculated only in patients with 5 consecutive 
measurements, did not show a significant differ-
ence between the groups (Fig. 4) either, although 
a similar trend was observed (TH 7,343 ± 5,742 
vs. control 14,361 ± 10,197, p = 0.08).
Discussion 
Cardiogenic shock is a systemic clinical syn-
drome. Therapeutic strategies with global systemic 
effects may offer additional benefit over standard 
cardiac support. TH may potentially offer systemic 
beneficial physiologic effects, including the prob-
ability to improve post-ischemic cardiac function 
and hemodynamics, decrease myocardial damage, 
and reduce end-organ injury from prolonged hy-
poperfusion. Favorable effects of TH have been 
demonstrated in ischemic animal models of CS 
by reduction of ischemia/reperfusion injury after 
urgent revascularization for AMI. In humans, 
3 studies showed decreased infarct size in patients 
with acute non-complicated infarcts treated with 
intravascular cooling. Clinical experience of TH 
in CS is limited. Several case reports and case 
series of TH in patients with CS, limited to pedi-
atric and adult cardiac surgery patients, have been 
described. Patients with CS following AMI have 
not been included.
The present study demonstrates that using 
a combination of an infusion of cold saline together 
with a disposable suit to induce mild hypothermia 
in patients with acute coronary syndrome com-
plicated with pump failure CS is feasible and safe 
without significant door to balloon delay. No signifi-
cant difference in clinical event rate was observed 
between the groups.
Limitations of the study
The primary aim of this study was to as-
sess the safety and feasibility of hypothermia in 
AMI complicated with CS. Survival and MI size 
reduction assessed by cardiac biomarkers was 
a secondary end point, and even though a significant 
reduction was not observed, these results should 
be interpreted with caution due to the small num-
ber of patients, the nature of the control group 
(retrospective, non-consecutive) and infarct size 
estimated only by biomarkers.
Conclusions
The results of the present study indicate that 
TH as an adjunctive therapy in STEMI patients 
complicated with CS, applied before reperfusion, is 
clinically feasible and safe without significant delay 
in time to reperfusion. Larger clinical studies are 
needed to evaluate the potential clinical efficacy 
of this approach to treat CS in the setting of AMI.
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